
Chiasma, Inc. Revenue 2011-2025 | CHMA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Chiasma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 1.11 M | - | - | - | - | - | 13.2 M | 73.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.1 M | 1.11 M | 29.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
Pharming Group N.V.
PHAR
|
186 M | $ 17.91 | -1.0 % | $ 7.59 B | ||
|
InflaRx N.V.
IFRX
|
166 K | $ 1.09 | -4.82 % | $ 152 M | ||
|
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
912 K | $ 1.15 | -1.71 % | $ 6.27 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
18.1 M | $ 4.78 | -0.31 % | $ 793 M | ||
|
Aclaris Therapeutics
ACRS
|
18.7 M | $ 3.03 | -0.49 % | $ 234 M | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | ||
|
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | ||
|
Ascendis Pharma A/S
ASND
|
364 M | $ 209.39 | -1.61 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | ||
|
Aptevo Therapeutics
APVO
|
3.11 M | $ 0.6 | -35.8 % | $ 166 K | ||
|
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.66 | -1.49 % | $ 424 M | ||
|
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.12 | 0.81 % | $ 7.51 B | ||
|
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 0.22 | 24.46 % | $ 479 M | ||
|
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
482 M | $ 94.72 | -0.33 % | $ 27.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 27.09 | 1.04 % | $ 1.31 B | ||
|
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | ||
|
Anika Therapeutics
ANIK
|
167 M | $ 9.6 | 1.27 % | $ 141 M | ||
|
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | ||
|
Zai Lab Limited
ZLAB
|
399 M | $ 18.4 | -0.97 % | $ 18.2 B | ||
|
Catalyst Biosciences
CBIO
|
113 M | $ 12.33 | -0.29 % | $ 812 M | ||
|
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
2.08 B | $ 584.81 | -1.07 % | $ 44.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
66.4 M | $ 2.44 | -3.56 % | $ 15.3 M | ||
|
AstraZeneca PLC
AZN
|
54.1 B | $ 92.79 | 0.37 % | $ 96.9 B | ||
|
ChromaDex Corporation
CDXC
|
99.6 M | - | -0.88 % | $ 598 M | ||
|
Certara
CERT
|
385 M | $ 8.9 | -0.17 % | $ 1.43 B | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K |